Everest Medicines (1952) Stock Overview
A biopharmaceutical company, engages in the discovery, license-in, development, and commercialization of therapies and vaccines to address critical unmet medical needs in Greater China and other Asia Pacific markets. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 1952 from our risk checks.
1952 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.
Read full narrativeEverest Medicines Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$32.82 |
| 52 Week High | HK$77.55 |
| 52 Week Low | HK$31.70 |
| Beta | 1.54 |
| 1 Month Change | -16.66% |
| 3 Month Change | -17.45% |
| 1 Year Change | -31.98% |
| 3 Year Change | 134.09% |
| 5 Year Change | -52.57% |
| Change since IPO | -54.89% |
Recent News & Updates
1952: Ulcerative Colitis Franchise Will Drive Long Term Upside Potential
Analysts have adjusted their price target for Everest Medicines to HK$50.16, a change they link to small refinements in the discount rate, revenue growth, profit margin and future P/E assumptions rather than a shift in the underlying narrative. What's in the News China's National Medical Products Administration approved the New Drug Application for VELSIPITY (etrasimod arginine tablets) for adults with moderately to severely active ulcerative colitis who have not responded adequately to, lost response to, or were intolerant of conventional therapy or a biologic agent in China (Key Developments).1952: Ulcerative Colitis Launch Will Drive Long Term Upside Potential
Analysts have trimmed their fair value estimate for Everest Medicines from about HK$53.11 to around HK$50.16. This reflects slightly higher discount rate assumptions and a more conservative future P/E multiple, while revenue growth and profit margin expectations remain broadly unchanged.1952: Ulcerative Colitis Launch Will Drive Upside Despite Trimmed Outlook
Analysts have trimmed their price target on Everest Medicines to HK$53.11 from HK$56.76 as updated assumptions reflect revised revenue growth, profit margin expectations and a higher future P/E multiple. What's in the News The National Medical Products Administration of China approved the New Drug Application for VELSIPITY (etrasimod arginine tablets) for adults with moderately to severely active ulcerative colitis who have not responded adequately to conventional therapy or biologics in China (Key Developments).1952: New Renal Licensing Deal And Ulcerative Colitis Launch Will Drive Upside
Analysts now see a lower fair value for Everest Medicines, trimming the HK$58.14 price target to about HK$56.76 as they factor in slightly higher discount rates, a modestly softer revenue growth outlook, reduced profit margin assumptions and a higher future P/E multiple. What's in the News China's National Medical Products Administration approved the New Drug Application for VELSIPITY (etrasimod arginine tablets) for adults with moderately to severely active ulcerative colitis who have not had adequate outcomes or tolerance with conventional therapy or biologic agents in China, with approval supported by Asian and global Phase 3 data showing statistically significant and clinically meaningful efficacy outcomes and a safety profile consistent with earlier studies (Key Developments).Recent updates
1952: Ulcerative Colitis Franchise Will Drive Long Term Upside Potential
Analysts have adjusted their price target for Everest Medicines to HK$50.16, a change they link to small refinements in the discount rate, revenue growth, profit margin and future P/E assumptions rather than a shift in the underlying narrative. What's in the News China's National Medical Products Administration approved the New Drug Application for VELSIPITY (etrasimod arginine tablets) for adults with moderately to severely active ulcerative colitis who have not responded adequately to, lost response to, or were intolerant of conventional therapy or a biologic agent in China (Key Developments).1952: Ulcerative Colitis Launch Will Drive Long Term Upside Potential
Analysts have trimmed their fair value estimate for Everest Medicines from about HK$53.11 to around HK$50.16. This reflects slightly higher discount rate assumptions and a more conservative future P/E multiple, while revenue growth and profit margin expectations remain broadly unchanged.1952: Ulcerative Colitis Launch Will Drive Upside Despite Trimmed Outlook
Analysts have trimmed their price target on Everest Medicines to HK$53.11 from HK$56.76 as updated assumptions reflect revised revenue growth, profit margin expectations and a higher future P/E multiple. What's in the News The National Medical Products Administration of China approved the New Drug Application for VELSIPITY (etrasimod arginine tablets) for adults with moderately to severely active ulcerative colitis who have not responded adequately to conventional therapy or biologics in China (Key Developments).1952: New Renal Licensing Deal And Ulcerative Colitis Launch Will Drive Upside
Analysts now see a lower fair value for Everest Medicines, trimming the HK$58.14 price target to about HK$56.76 as they factor in slightly higher discount rates, a modestly softer revenue growth outlook, reduced profit margin assumptions and a higher future P/E multiple. What's in the News China's National Medical Products Administration approved the New Drug Application for VELSIPITY (etrasimod arginine tablets) for adults with moderately to severely active ulcerative colitis who have not had adequate outcomes or tolerance with conventional therapy or biologic agents in China, with approval supported by Asian and global Phase 3 data showing statistically significant and clinically meaningful efficacy outcomes and a safety profile consistent with earlier studies (Key Developments).
1952: China Ulcerative Colitis Drug Approval Will Drive Future Upside
Narrative Update on Everest Medicines Analysts have lifted their HK$ price target for Everest Medicines, reflecting higher assessed fair value alongside updated views on revenue growth, profit margins and a lower expected future P/E multiple. What's in the News China's National Medical Products Administration approved the New Drug Application for VELSIPITY (etrasimod arginine tablets) for adults with moderately to severely active ulcerative colitis who have not responded adequately or are intolerant to conventional or biologic therapies in China, based on data from the Asian Phase 3 ENLIGHT UC study and the global ELEVATE UC Phase 3 program (Key Developments).1952: New Renal Licensing Deal And Shareholder Meeting Will Support Future Upside
Analysts have made a marginal upward adjustment to their fair value estimate for Everest Medicines to HK$58.14, reflecting small model updates to the discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News Everest Medicines (China) Co., Ltd.1952: Patent Protection And Upcoming Shareholder Meeting Will Support Future Upside
Analysts have trimmed their fair value estimate for Everest Medicines to US$58.13 from US$64.56, citing revised assumptions around discount rates, profit margins and future P/E, which offset slightly higher revenue growth expectations. What's in the News Everest Medicines has scheduled a special or extraordinary shareholders meeting for February 24, 2026 at 10:00 China Standard Time, giving investors a key date to watch for company level decisions (company announcement).Revenues Not Telling The Story For Everest Medicines Limited (HKG:1952)
There wouldn't be many who think Everest Medicines Limited's ( HKG:1952 ) price-to-sales (or "P/S") ratio of 14x is...
1952: Ophthalmology Expansion Will Face Overvaluation Risk Despite Improved Profit Outlook
Analysts have raised their price target on Everest Medicines from 25.58 to 30.34 as they factor in stronger expected revenue growth, improved profit margins, and a slightly higher discount rate, offset in part by a modestly lower future P/E multiple. What's in the News Entered an exclusive license agreement with Visara Inc.Rising Demand In China And Asia-Pacific Will Expand Biotech Reach
Everest Medicines' analyst price target has been adjusted downward from $29.16 to $26.79, reflecting analysts' moderated growth and profitability expectations in light of updated risk assessments. What's in the News Everest Medicines provided earning guidance for the full year 2025, projecting revenue of RMB 1.6 billion to RMB 1.8 billion, with RMB 1.2 billion to RMB 1.4 billion expected from NEFECON sales (Key Developments).Rising Demand In China And Asia-Pacific Will Expand Biotech Reach
Driven by a meaningful improvement in net profit margin and a notable drop in future P/E, analysts have modestly raised Everest Medicines’ fair value, with the consensus price target increasing from HK$62.67 to HK$64.56. What's in the News Everest Medicines expects full-year 2025 revenue of RMB 1.6–1.8 billion, with RMB 1.2–1.4 billion from NEFECON sales.Rising Demand In China And Asia-Pacific Will Expand Biotech Reach
The recent upward revision in Everest Medicines’ consensus Analyst Price Target is primarily driven by a modest increase in its expected future P/E multiple, lifting fair value from HK$61.36 to HK$62.67. What's in the News Everest Medicines expects 2025 revenue of RMB 1.6–1.8 billion, with NEFECON sales contributing RMB 1.2–1.4 billion.NRDL Approval And Pipeline Efforts Will Counterbalance Potential Risks
The notable increase in Everest Medicines’ consensus price target reflects a significant improvement in net profit margin alongside a sharp decline in future P/E, indicating enhanced profitability and a more attractive valuation, with the target rising to HK$57.29. What's in the News The board will meet to discuss interim results for the first half of 2025 and other business.Everest Medicines Limited's (HKG:1952) Shares Climb 26% But Its Business Is Yet to Catch Up
Everest Medicines Limited ( HKG:1952 ) shareholders would be excited to see that the share price has had a great month...Everest Medicines (HKG:1952) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...The Price Is Right For Everest Medicines Limited (HKG:1952) Even After Diving 26%
Everest Medicines Limited ( HKG:1952 ) shareholders won't be pleased to see that the share price has had a very rough...
NRDL Approval And Pipeline Efforts Will Counterbalance Potential Risks
Dependence on NEFECON's success and market strategies in the IgAN space may not deliver the expected revenue, posing financial risks.Does Everest Medicines (HKG:1952) Have A Healthy Balance Sheet?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Everest Medicines Limited (HKG:1952) Annual Results: Here's What Analysts Are Forecasting For This Year
Last week, you might have seen that Everest Medicines Limited ( HKG:1952 ) released its full-year result to the market...A Look At The Fair Value Of Everest Medicines Limited (HKG:1952)
Key Insights The projected fair value for Everest Medicines is HK$19.06 based on 2 Stage Free Cash Flow to Equity With...Shareholder Returns
| 1952 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | -5.0% | -2.1% | 1.1% |
| 1Y | -32.0% | 54.3% | 19.7% |
Return vs Industry: 1952 underperformed the Hong Kong Biotechs industry which returned 55.3% over the past year.
Return vs Market: 1952 underperformed the Hong Kong Market which returned 20.3% over the past year.
Price Volatility
| 1952 volatility | |
|---|---|
| 1952 Average Weekly Movement | 8.0% |
| Biotechs Industry Average Movement | 8.6% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in HK Market | 15.1% |
| 10% least volatile stocks in HK Market | 3.5% |
Stable Share Price: 1952 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 1952's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 812 | Rogers Luo | www.everestmedicines.com |
Everest Medicines Limited, a biopharmaceutical company, engages in the discovery, license-in, development, and commercialization of therapies and vaccines to address critical unmet medical needs in Greater China and other Asia Pacific markets. It pipeline includes Nefecon, an oral formulation of budesonide for the treatment of immunoglobulin nephropathy (IgAN); Xerava, a fully synthetic fluorocycline intravenous antibiotic for the treatment of infections caused by susceptible gram-positive, gram-negative, and anaerobic pathogens; Taniborbactam, a beta-lactamase inhibitor (BLI) which is in phase 3 clinical trial for the treatment of patients with serious bacterial infections; and Etrasimod, an oral selective sphingosine 1-phosphate (S1P) receptor modulator which is in phase 3 clinical trial for to treat moderate-to-severe active ulcerative colitis. The company provides Zetomipzomib, an immunoproteasome inhibitor that is in phase 2b clinical trial, for a range of immune mediated disorders, including lupus nephritis; EVER001, a covalent reversible Bruton’s tyrosine kinase (BTK) inhibitor which is in the phase 1b clinical trial for the treatment of renal diseases; and mRNA platform therapeutic vaccines for cancer and autoimmune diseases.
Everest Medicines Limited Fundamentals Summary
| 1952 fundamental statistics | |
|---|---|
| Market cap | HK$11.53b |
| Earnings (TTM) | -HK$342.72m |
| Revenue (TTM) | HK$1.96b |
Is 1952 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1952 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.71b |
| Cost of Revenue | CN¥524.82m |
| Gross Profit | CN¥1.18b |
| Other Expenses | CN¥1.48b |
| Earnings | -CN¥297.77m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.85 |
| Gross Margin | 69.25% |
| Net Profit Margin | -17.45% |
| Debt/Equity Ratio | 16.3% |
How did 1952 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/08 13:47 |
| End of Day Share Price | 2026/05/08 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Everest Medicines Limited is covered by 13 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Bo Li | BofA Global Research |
| Jin Zhang | China International Capital Corporation Limited |
| Ziyu He | China International Capital Corporation Limited |